Drug Profile
Research programme: pegylated therapeutics - Belrose Pharma
Alternative Names: EZN 3008; PEG C1 esterase inhibitor; Pegylated anti-TNF-α antibody; Pegylated C1 esterase inhibitor; Pegylated interferon-β-1b - EnzonLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator Enzon Pharmaceuticals
- Developer Belrose Pharma; Enzon Pharmaceuticals
- Class Antibodies; Drug conjugates; Interferons; Oligonucleotides; Peptides; Proteins; Small molecules; Vascular disorder therapies
- Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Immunomodulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Multiple sclerosis
- Discontinued Hereditary angioedema
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Hereditary angioedema in USA (IV)
- 21 Mar 2023 Discontinued - Preclinical for Hereditary angioedema in USA (SC)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (IV)